C2N and Eisai Collaborate to Build Awareness and Real-World Evidence for Blood-Based Assays for Cognitive Impairment in Clinical Practice Outside of Clinical Trial Settings

/PRNewswire/ -- C2N Diagnostics and Eisai Inc. today announced the Companies have entered into a memorandum of understanding that will seek to build awareness...

Related Keywords

Australia ,New Zealand ,Russia ,Ivan Cheung ,Libby Holman ,Adam Shapiro ,Joel Braunstein ,Milken Institute ,Linkedin ,Eisai Inc ,Eisai Europe Ltd ,Eisai Co Ltd ,Alzheimer Disease International ,Biomarkers For Cognition Health ,United Nations Sustainable Development Goals Sdgs ,Global Alzheimer ,Disease Officer ,Senior Corporate Officer ,Its Blood Based Biomarkers ,Clarity Through Innovation ,P Tau Multi Analyte Assay ,United Nations Sustainable Development Goals ,Middle East ,World Alzheimer Report ,Building Workforce Capacity ,Improve Detection ,